Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/461328


Czech Republic Pharmaceuticals and Healthcare Report Q3 2007


Description: The Czech Republic Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

The health sector in the Czech Republic is in a state of flux as detailed in the Q307 Czech Republic Pharmaceuticals & Healthcare Report. Proposed reforms to the system include the introduction of flat charges for prescriptions, as well as fees for both doctor consultations and hospital visits. We expect these changes to be deeply controversial with industry stakeholders and patient groups likely to offer strong resistance.

The Czech Republic’s pro-business governing party the Civil Democrats is keen to curb consumption in the health sector, with Health Minister Tomáš Julínek championing the implementation of fees at the point-of-delivery. Opposition is fiercest from the pro-market right of the political spectrum, which wishes to see even greater liberalisation, with commentators seeing the two camps as irreconcilable.

Meanwhile, we expect draft amendments to the national tax legislation to have a deflationary impact on consumption, as they propose an increase in the VAT on medicines from 5% to 9%. Despite the downside afforded by these reforms we remain optimistic about the strength of the Czech drug sector. We expect the market to grow by an average annual rate of 6.98% from US$2.89bn in 2006 to US$4.05bn in 2011. Recent solid economic growth has contributed to stabilising the market, enabling greater out-of pocket spending, while industry is likely to continue to attract foreign investment, encouraged by the advantages that the market offers within the EU. In fact, the overall health of the economy may end up negating the deflationary impact of the VAT hike, with consumer-spending power remaining strong.

Drugmakers in the country will also be encouraged by the desire of the government to introduce a 15% flat tax rate and a 19% corporate tax rate by 2010. Such tax systems are common in Central & Eastern Europe and are designed to stimulate business. In pharmaceuticals, this could result in more funds being made available for R&D. Local drugmakers such as Zentiva are expected to be affected by the new prescription fee system. However, there is hope offered by the example of Slovakia. A similar system introduced in this country but after a year generic sales recovered, although they remained depressed for branded drugs.

Meanwhile, the Czech Republic has retained it lead at the top of our Business Environment Rankings for Central & Eastern Europe, although only just. The country improved its score marginally after an upwards revision of its rating for long-term political risk. However, Bulgaria and Estonia have both increased their overall scores and are now on level terms.


Contents: Executive Summary
Czech Republic Pharmaceuticals And Healthcare Industry SWOT
Czech Republic Political SWOT
Czech Republic Economic SWOT
Czech Republic Business Environment SWOT
Czech Republic: Business Environment Rankings
Table: Central And Eastern Europe Businsess Environment Rankings
Business Environment Ranking
Economics - Long-Term Risk
Politics - Long-Term Risk
Regulatory Barriers
Domestic Sector Threat
Market Growth Potential
Market Size Ranking
Regional Summary
Czech Republic: Market Summary
Regulatory Regime
Intellectual Property Environment
Pricing And Reimbursement Issues
Pharmacy Sector
Hospital Sector
Healthcare Sector
Table: Health Expenditure Indicators
Research And Development Sector
Industry Forecast Scenario
Overall Market Forecast
Table: Czech Republic Drug Market Forecast Indicators
Key Growth Factors - Industry
Table: Czech Republic Health Expenditure Forecast Indicators
Key Growth Factors - Macroeconomic
Table: Czech Republic - Economic Activity
Prescription And OTC Market Forecasts
Table: Czech Republic Prescription Drug Market Indicators
Table: OTC Drugs Market Forecast Indicators
Generics And Branded Market Forecasts
Table: Czech Republic Generics And Branded Market Forecast Indicators
Export/Import Forecasts
Table: Czech Republic Trade Indicators (US$mn)
Other Healthcare Data Forecasts
Table: Socio-Demographic Indicators
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Wholesale
Retail
Table: Pharmacies And Pharmacy Market Ratios
Company Monitor
AstraZeneca
Bristol-Myers Squibb
Sanofi-Aventis
Walmark
Zentiva (incorporating Sicomed)
Our Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Sources


Companies Mentioned - AstraZeneca - Bristol-Myers Squibb - Sanofi-Aventis - Walmark - Zentiva (incorporating Sicomed)


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/461328

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 25/11/2009 19:23:17
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Czech Republic Pharmaceuticals and Healthcare Report Q3 2007
Web Address:
http://www.researchandmarkets.com/reports/461328
Office Code:
OC8HJNMPMSTQQ

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €440.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 25/11/2009 19:23:17

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)